# A Global Randomized Trial Evaluating the FARAFLEX™ Mapping and Pulsed Field Ablation System With Electrographic Flow Mapping in Patients Undergoing Repeat Ablation for Atrial Fibrillation

Study · id `cardio:ct-nct07820930` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07820930](<https://clinicaltrials.gov/study/NCT07820930>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07820930

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 650 participants.

## Technical summary

Registry record NCT07820930. Randomized; no masking; primary purpose treatment. Start 2026-11 (anticipated); primary completion 2029-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 650 participants (planned count; ClinicalTrials.gov record NCT07820930, source copy `cardio:ctgov-nct07820930-2026-10-23`, retrieved 2026-10-26)
- Planned start: 2026-11 (anticipated) (ClinicalTrials.gov record NCT07820930, source copy `cardio:ctgov-nct07820930-2026-10-23`, retrieved 2026-10-26)
- Primary completion: 2029-07 (anticipated) (ClinicalTrials.gov record NCT07820930, source copy `cardio:ctgov-nct07820930-2026-10-23`, retrieved 2026-10-26)
- Completion: 2031-07 (anticipated) (ClinicalTrials.gov record NCT07820930, source copy `cardio:ctgov-nct07820930-2026-10-23`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07820930-2026-10-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Global Randomized Trial Evaluating the FARAFLEX™ Mapping and Pulsed Field Ablation System With Electrographic Flow Mapping in Patients Undergoing Repeat Ablation for Atrial Fibrillation
- Acronym: ReDEFINE-AF
- Condition: Atrial Fibrillation (AF)
- Condition: Persistent Atrial Fibrillation (PersAF)
- Condition: Paroxysmal Atrial Fibrillation (PAF)
- Intervention (Device): FARAFLEX Mapping and Pulsed Field Ablation System
- Lead sponsor: Boston Scientific Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Boston Scientific (`cardio:boston-scientific`)

## Provenance

Content hash: b8ee4c68589de7d3f9403c3c8f0ce02cb5360085a00578853b15cdd4bbe94f33
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
